209. Infections in Immunocompromised Hosts
Saturday, October 6, 2018: 10:30 AM-11:45 AM
Room: S 214-216

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • explain the ideal empiric treatment for febrile neutropenic patient

  • discuss recommendations for the immunocompromised patient and explain the gaps of knowledge associated with these recommendations

  • review infections associated with immunomodulators

Target Audience: Clinicians, Epidemiologists, Fellows, Infection preventionists, Infectious diseases pediatricians, Infectious diseases physicians, Pharmacists

Tracks: Trainee, Pediatric ID, Adult ID

Moderators:  Ella Ariza-Heredia, MD, The University of Texas MD Anderson Cancer Center and Jennifer Schuster, MD, Children's Mercy Kansas City

10:30 AM
Febrile Neutropenia
Alison Freifeld, MD

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™


E. Ariza-Heredia, Oxford Immunotec: Grant Investigator , Research grant . Theravance Biopharma: Scientific Advisor , Scientific Advisor .

J. Schuster, Satchel Health: Shareholder , shareholder in telehealth company . Elsevier: Guest Editor , Editor Honoraria . Merck: Investigator , Research support . AAP: Editorial board , Travel reimbursement and editorial board .

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.